The aim of this study was to replicate our earlier finding of elevated angiotensin-converting enzyme (ACE) hi cerebrospinal fluid (CSF) in schizophrenia and to elucidate the role of neuroleptic treatment hi this phenomenon. Drug-free and medicated patients with acute schizophrenic psychoses, as well as healthy controls were recruited. Levels of ACE were measured hi CSF and serum from 7 drug-free patients, 36 neuroleptic-treated patients, and 19 healthy control subjects. Although ACE levels in CSF did not differ between patients and controls, the drug-free patients showed significantly lower levels than the neuroleptictreated patients. Serum ACE did not differ between groups. The elevation of CSF ACE may be more prominent hi patients with deficit symptoms than hi those with mainly psychotic symptoms.
The renin-angiotensin system (RAS) is a complex system of peptides regulating blood pressure and water homeostasis. The only regulated reaction in the peripheral RAS is the secretion of renin in response to changes in salt and water intake. Renin catalyzes the formation of angiotensin I (AT I), which is further converted to the biologically active octapeptide angiotensin n (AT II) by the dipeptidase angiotensin-converting enzyme (ACE), peptidyldipeptidase A, kininase II, E.C. 3.4.15.1. ACE is a gene product believed to be present at constant concentrations, independent of water balance (Poulsen and Jacobsen 1993) . It is a heavily glycosylated protein (molecular weight, 140,000-170,000 daltons) and is mainly membrane-bound.
All components of the RAS are also present in the central nervous tissue, forming the brain RAS (Ganten et al. 1971; Printz et al. 1982; Jin et al. 1988; Bunnemann et al. 1992) . ACE exhibits broad substrate specificity and also catalyzes the degradation of bradykinin, neurotensin, substance P, enkephalins, and other peptides (Terenius and Nyberg 1988; Yoshida and Nosaka 1990; Welches et al. 1993) . ACE is found in the plasma membranes of neurons (Horsthemke et al. 1984; Koshiya et al. 1985) and probably influences peptidergic neurotransmission.
The circulating AT II of me peripheral RAS increases vascular tonus, stimulates secretion of aldosterone, and exerts trophic effects on cardiovascular structures. The brain RAS appears to be regulated independent of the peripheral RAS. The brain RAS is pressogenic and dipsogenic; it increases sodium intake, stimulates the release of arginine vasopressin (AVP) from the posterior pituitary, and may also be involved in the regulation of sexual behavior and reproduction, as well as in cognitive processing and pain perception (Wright and Harding 1992) .
Water homeostasis is frequently disturbed in patients with psychiatric disorders. Polydipsia occurs in more than 20 percent of chronic psychiatric inpatients, especially in chronic schizophrenia. Nearly one-third of these patients develop water intoxication characterized by profound hyponatremia (de Leon et al. 1994) . In selected cases, the polydipsia is complicated by a syndrome of inappropriate AVP secretion (SIADH) (Raskind et al. 1975; Vieweg et al. 1984; Delva et al. 1990 ). The osmotic threshold for AVP secretion seems to be reduced in psychotic patients with polydipsia and hyponatremia ("reset osmostat") (Hariprasad et al. 1980; Goldman et al. 1988) , which may implicate stimulated central RAS activity.
The angiotensin peptides may also play a role as growth factors and developmental regulators in the brain. The product of the human mas oncogene is an angiotensin-sensitive receptor that appears to be expressed exclusively in the brain ). The mas oncogene may be rather selectively expressed in the neurons of the limbic system and frontal cortex (Bunnemann et al. 1990 ), areas of special significance in the pathophysiology of schizophrenia. Beckmann et al. (1984) reported decreased levels of cerebrospinal fluid (CSF) ACE in acutely paranoid males with schizophrenia compared to neurological control patients. Because alterations in CSF ACE levels have been observed in various neuropsychiatric conditions, such as neurosarcoidosis (Oksanen et al. 1985 ), Alzheimer's disease, Parkinson's disease, and supranuclear palsy (Zubenko et al. 1985; Konings et al. 1993 Konings et al. , 1994 , use of diagnostic lumbar punctures from patients with neurological symptoms and pain as control samples may have biased their study. Beckmann et al. (1984) also found a significant positive correlation between CSF ACE and the dose of neuroleptics in schizophrenia patients, while untreated patients (n = 13) exhibited nonsignificantly lower levels of CSF ACE than neuroleptic-treated patients (n -15). Our group previously reported elevated levels of CSF ACE in a study of healthy controls and severely disabled, neuroleptic-treated chronic (mean duration of illness, 18.5 ± 12.2 years) schizophrenia inpatients (n = 14) with normal serum sodium levels and urine specific gravity (Wahlbeck et al. 1993) . Because the elevation of CSF ACE found in these studies could have emerged from the neuroleptic medication used and because our previous study might have been compromised by the small sample size, we undertook the current study to replicate the finding of elevated CSF ACE in a larger controlled study of less chronic patients, including both drug-treated and neuroleptic-free groups.
Our hypothesis was that the elevated levels of CSF ACE reflect elevated activity of the central RAS, which in some schizophrenia patients may contribute to polydipsia and even water intoxication. Activation of the central RAS may represent autonomous production of ACE in neurons or monocytic cells or it may be a response to neuroleptic treatment. The alterations in RAS may also reflect a disturbance in the regulation of neuronal growth and differentiation because angiotensins seem to be neural growth factors.
Methods
The series comprised 56 unmedicated, acutely psychotic Caucasian consecutively admitted patients who were admitted voluntarily or involuntarily to psychiatric wards at Hesperia Hospital, Helsinki, Finland, and 20 healthy Caucasian controls from the hospital staff. Subjects over the age of 65 years or suffering from serious physical diseases, alcoholism, or drug abuse, or ongoing neuroleptic medication were excluded from the series. Only patients with a DSM-TV (American Psychiatric Association 1994) psychosis in the schizophrenia spectrum, that is, a diagnosis of schizophrenia, schizophreniform disorder, or schizoaffective disorder, were included in the present study (n = 43). Patients with other diagnoses were excluded (n -13).
The included patients had a mean number of hospitalizations, including the current episode, of 4.7 ± 6.5 (range, 1-33); 17 patients were being hospitalized for the first time. The duration of psychotic symptoms before admission was 159 ±319 days. The diagnoses were schizophreniform disorder (n = 14); schizophrenia, paranoid type (n = 13); schizophrenia, undifferentiated type (n = 13); schizophrenia, disorganized type (n = 1); and schizoaffective disorder (n = 2).
The controls were unmedicated, normotensive paid subjects from the hospital staff recruited through the personnel paper. Subjects with a family history of psychiatric illness in first-degree relatives were excluded before the interview. The control subjects were medication-free with the exception of three women who used oral contraceptives. Psychiatric diagnoses in the control subjects were excluded by administration of the Structured Clinical Interview for DSM-III-R (SCID; Spitzer et al. 1988 ) by a clinical psychiatrist (K.W.). Of the 20 subjects interviewed, 1 was excluded after a diagnosis of personality disorder, mixed type. In order to obtain circumstances comparable to the patient group's, the control subjects were admitted to a psychiatric ward 1 day prior to sampling.
Written informed consent for die research procedure was obtained from all subjects and, when necessary, from tfieir guardians after the nature of the study had been fully explained. Approvals by the Ethics Committee of Hesperia Hospital and the Ethics Committee of the Department of Psychiatry, University of Helsinki, were obtained.
All 43 patients had been unmedicated for at least 3 months before hospital admission. Seven were drug-free before lumbar puncture; the other 36 were medicated during their hospital stay (mean time before lumbar puncture, 7.6 ±11.5 days) with chlorpromazine (270 ± 119 mg, 22 patients), haloperidol (22.4 ± 13.3 mg, 13 patients), zuklopenthixol (55 ± 24 mg, 8 patients), promazine (120 ± 45 mg, 5 patients), perphenazine (15.9 ± 5.9 mg, 5 patients), and chlorprothixene (267 ± 58 mg, 3 patients). Two patients used lithium carbonate (900 ± 300 mg) and three used benzodiazepines (oxazepam, 2 patients; diazepam, 1 patient). The mean neuroleptic dose for the medicated patients was 416 ± 275 mg chlorpromazine equivalents.
The patients were rated according to a revised operationalized 18-item version of the Brief Psychiatric Rating Scale (BPRS; Guy 1976), each item being scored from 0 to 6, and the 12-item schizophrenia subscale of the Comprehensive Psychiatric Rating Scale (CPRS; Montgomery et al. 1987) . The mean total scores were 55.3 ± 12.7 and 39.6 ± 8.3, respectively.
The lumbar puncture was performed in the lateral decubitus position immediately after blood had been drawn between 8 and 9 a.m. following overnight fasting and 30 minutes of bed rest. In the schizophrenia group, the samples were taken on day 6.6 ±10.8 (median; day 4) after admission and in the control group on day 2.0 ± 0.0 after admission.
Fractionated aliquots of the CSF were collected in chilled tubes and immediately frozen at -70 °C until assayed. Only CSF samples without blood contamination and with a normal cell count were accepted. Blood samples were taken from an antecubital vein and promptly centrifuged at 3,000 rpm for 10 minutes at 4 °C. The separated plasma and serum were immediately frozen at -70 °C until assayed.
ACE concentrations were determined with a sensitive inhibitor binding assay (Fyhrquist et al. 1984) in duplicate samples of CSF and serum at the Minerva Institute for Medical Research, Helsinki, Finland. One unit of ACE corresponded to 1 (xmol of substrate converted per minute at 37 °C, as defined by Cushman and Cheung (1971) . The detection limit of the assay, defined as >2 standard deviations (SDs) deflection from zero standard, was 0.023 units per liter, which corresponds to about 0.5 ng of enzyme. The assay is based on specific binding of labeled inhibitor to the active center of the enzyme. This eliminates interference from enzymes other than ACE, which is a considerable risk in assays based on radiochemically labeled substrates.
Descriptive statistical data are presented as means ± SD. Statistical probabilities (p) were calculated with unpaired t tests for normally distributed variables and with Mann-Whitney U tests for non-normal variables. Normality assumptions were tested using KolmogorovSmirnov and Lilliefors' tests. Because of different group sizes and differing variances, all t tests were checked with Mann-Whitney U tests. Categorical variables were tested with Fisher's exact test. Correlations were calculated with Spearman's correlation coefficient (r). Corrections for number of correlations were made with the Bonferroni method. Analysis of variance (ANOVA) was performed for normally distributed variables using SYSTAT computer software (SYSTAT 1992) .
Gender distribution did not differ between groups (Fisher's exact test, p = 0.59); the patient group had 22 females and 21 males, while the control group had 8 females and 11 males. Patients and controls did not differ with respect to age (33.9 ± 9.6 and 32.4 ± 10.6 years, respectively), systolic (133 ± 14 and 126 ± 17 mmHg, respectively) or diastolic (84 ±11 and 80 ± 10 mmHg, respectively) blood pressure, or CSF protein levels (364 ± 95 and 380 ± 116 mg/L, respectively).
The neuroleptic-treated and drug-free patients did not differ with respect to age (33.4 ± 8.5 and 36.6 ± 14.5 years, respectively), systolic (131 ± 18 and 134 ± 13 mmHg, respectively) or diastolic (83 ± 15 and 84 ± 10 mmHg, respectively) blood pressure, or CSF protein levels (366 ± 93 and 353 ± 118 mg/L, respectively). The main determinator of group allocation was the possibility of arranging for a spinal tap soon after admission. When a lumbar puncture could not be arranged quickly, the patients were medicated with neuroleptics for ethical reasons. Thus, the time lag from admission to spinal tap was significantly (U = 23.0, df= 42, p = 0.001) shorter in the drug-free group (1.0 ±1.9 days) than in the neuroleptictreated group (7.6 ±11.5 days). Gender distribution, legal status, duration of illness, and number of hospitalizations did not differ between neuroleptic-treated and drug-free patients, nor were there any statistically significant differences in the total BPRS or CPRS scores.
Results
Serum ACE levels did not differ among the three groups. Drug-free patients had significantly lower levels of CSF ACE than neuroleptic-treated patients (U = 64.0, df = 41, p = 0.048). There was no significant difference in the levels of serum ACE (U = 86.0, df= 40, p = 0.46) or CSF total protein (U = 101.5, df= 41, p = 0.81) between the two patient groups. When ANOVA was performed for controls, neuroleptic-treated patients, and drug-free patients, there was a statistically significant effect of group on CSF ACE levels (table 1) .
There were no significant correlations between CSF or serum ACE levels and age, gender, height, or blood pressure in patients versus controls or in the treated versus drug-free subgroups. In the schizophrenia psychosis group, there were no significant correlations between CSF ACE level and number of hospitalizations, duration of current hospitaUzation, or duration of current psychotic episode. In order to define blood brain barrier deficits, which may influence CSF protein levels, the ratio of CSF albumin to serum albumin was calculated for all patients. The results were in the range of 0.0015-0.0084, and they correlated significantly with the CSF protein values (r = 0.81, p < 0.001), but not with CSF ACE values. CSF ACE levels did not correlate with CSF protein levels either.
CSF ACE levels were negatively correlated with haloperidol dose (n = 12, r = -0.75, p = 0.005), but there were no other correlations with other neuroleptic dosages or with the total neuroleptic dose expressed in chlorpromazine equivalents. The significant negative correlation between CSF ACE level and haloperidol dose was lost when a partial correlation, adjusted for age, was performed (r = -0.31, df=9,p = 0.355). This was due to the fact that although age and CSF ACE level were not correlated in any other subgroup, a significant correlation (n = 12, r = 0.72, p = 0.008) was found in the patients treated with haloperidol. Another reason is that older patients were treated with smaller doses of haloperidol.
Serum or CSF ACE levels did not differ between patients treated with low-potency (e.g., chlorpromazine, chlorprothixene, and promazine) and high-potency (e.g., haloperidol, zuklopenthixol, and perphenazine) neuroleptics, nor did any individual neuroleptic seem to affect ACE levels differently from the others.
CSF ACE levels did not differ between the different diagnostic groups. No correlations between these levels and total BPRS or CPRS schizophrenia subscale total scores were found. When uncorrected correlations between CSF ACE levels and individual BPRS and CPRS item scorings were performed, significant negative correlations with symptom scores assessing the psychotic dimension (BPRS item 11; CPRS items 1, 9, 10, and 11) were found, while CPRS items "inability to feel" and "sadness" were positively correlated with CSF ACE levels. When correcting for chlorpromazine equivalents, these associations were found to be independent of neuroleptic medication. When a Bonferroni correction of significance levels was performed, only CPRS item 1 (feeling controlled) (r = 0.50, p = 0.012) and CPRS item 6 (inability to feel) (r = 0.50, p = 0.012) were correlated strongly enough to show statistical significance.
Excluding the patients treated with added lithium carbonate or those with schizoaffective disorder from the statistical analyses did not change the statistical significance of any of the findings. None of these patients were outliers in terms of CSF ACE values.
Discussion
The absence of correlations betweens CSF ACE and CSF protein levels, and between CSF ACE and CSF to serum albumin ratios indicate that CSF ACE was in all likelihood not contaminated with serum ACE. Accordingly, no correlation between CSF and serum ACE levels was found (n = 60, r = 0.14, p = 0.305).
Taken together, the results from this article and the two earlier studies of CSF ACE in schizophrenia (Beckmann et al. 1984; Wahlbeck et al. 1993 ) present a picture of increasing CSF ACE levels with duration of illness and neuroleptic treatment. Moreover, the current finding of lower CSF ACE levels in drug-free patients is consistent with a stimulating effect of neuroleptics on CSF ACE. Interestingly, long-term treatment with levodopa in Parkinson's disease also seems to increase CSF ACE levels (Konings et al. 1994) .
Although the pathophysiology of polydipsia was not the main objective of this study, our findings suggesting that neuroleptic medication affects the central RAS raise interesting questions concerning the influence of neuroleptics on water intake. The implications of our findings for an understanding of polydipsia in schizophrenia patients remain unclear, since the patients in this study were not included because of, nor were they assessed for polydipsia. If the influence of neuroleptics on the central RAS were to be unequivocally established, it would be important to measure CSF ACE levels in polydipsic patients on and off neuroleptics. Such studies should also attempt to control water intake and assess body water balance. Verghese et al. (1993) proposed that chronic dopamine D 2 receptor blockage with neuroleptics may increase central sensitivity to AT II and produce polydipsia. However, our findings point to increased enzymatic activity in the RAS as a function of neuroleptic treatment Because polydipsia existed before the era of neuroleptics, the use of neuroleptic medication cannot account for all cases of polydipsia, and antipsychotic treatment is still considered the treatment of choice in psychosis-associated polydipsia (Vieweg 1994) . Randomized controlled human studies are clearly needed to establish the usefulness of neuroleptics and/or ACE inhibitors in the treatment of polydipsia in psychosis.
Because there was no randomization between patient groups, a selection bias is possible; however, we found no differences between neuroleptic-treated and drug-free patients in background or baseline data. The greater variance of CSF protein and ACE levels in the drug-free group is probably due to the smaller group size. Although the duration of concurrent hospital treatment was shorter in the drug-free group, no correlation between CSF ACE level and days since admission was found.
The elevation of CSF ACE levels does not seem to be a function of the possible hypotensive effect of neuroleptics, since neither systolic nor diastolic blood pressure correlated with these levels. Moreover, there was no difference in CSF ACE levels between patients treated with low-potency neuroleptics known to decrease blood pressure and patients treated with high-potency neuroleptics.
Due to the naturalistic study design, older patients were found to have been significantly more often treated with chlorpromazine, while younger patients were preferably treated with haloperidol. A significant positive correlation was found between age and chlorpromazine dose (r = 0.52, p = 0.014), whereas a significant negative correlation was found between age and haloperidol dose (r = 0.59, p = 0.035). This diversity in .neuroleptic medication may hide potential age-related diversity in ACE levels in schizophrenia. Nevertheless, such an age diversity is not likely, since no correlations between age and serum or CSF ACE levels were found in any of the three study groups.
Patients who scored high on the psychotic symptom "feeling controlled" had lower CSF ACE levels than patients who scored lower on these symptoms. This is in accordance with Beckmann et al. (1984) , who found lower CSF ACE levels in patients with acute paranoid schizophrenia than in neurological controls (control subjects with nonspecific neurological symptoms which necessitated a diagnostic lumbar puncture). The deficit symptom "inability to feel" predicted higher CSF ACE values. Kirch et al. (1985) suggest that patients with predominantly negative symptoms have an increased risk of water intoxication, which may implicate activation of the central RAS. This is in accordance with our finding of a positive correlation between inability to feel (a negative symptom) and CSF ACE level.
To determine central RAS activity, it is crucial to determine the levels of the effector peptides, the angiotensins. However, accurate determination of AT II and the other AT I fragments are extremely difficult because of low concentrations, poor stability, and fluctuating levels. Angiotensin levels are influenced by the minute-to-minute regulation of renin concentration in response to body water fluctuation and are thus more difficult to interpret than ACE levels. To obtain reliable results in angiotensin assays, a mixture of an angiotensinase inhibitor and an ACE inhibitor must be added to the sample (Boddi et al. 1992 ). Although we made an effort to determine AT II levels from a subset of our CSF samples without additions, no traces could be found.
The elevated CSF ACE levels may have resulted from increased synthesis of the enzyme in neurons or monocytic cells, or it may reflect increased solubilization of ACE from cell membranes in the central nervous system. Interestingly, several in vivo studies have shown that neuroleptics may influence plasma membrane structures (Mori et al. 1980; Houtia et al. 1988; Tysnes et al. 1990 ). Hypothetically, neuroleptics may influence CSF ACE levels by altering membrane structure and increasing the ratio of soluble to membrane-bound ACE.
Replication of our previous finding of elevated ACE activity in schizophrenia psychoses was only partially achieved in that only neuroleptic-treated patients differed significantly from the drug-free patients in this respect. Based on our current knowledge of CSF ACE levels in schizophrenia psychoses, a new hypothesis can be constructed: CSF ACE levels, by some as yet unknown mechanism, may be elevated by neuroleptic treatment The elevation of CSF ACE level may be more prominent in patients with deficit symptoms than in those with mainly psychotic symptoms. The elevated CSF ACE levels may, together with other possible factors, cause polydipsia, stimulate secretion of AVP, and even affect neuron growth and differentiation in schizophrenia psychoses.
